Author: Mendoza, E. J.; Warner, B.; Safronetz, D.; Ranadheera, C.
Title: Crimean–Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures Cord-id: oktbb5wg Document date: 2018_4_20
ID: oktbb5wg
Snippet: Crimean–Congo haemorrhagic fever (CCHF) is a widespread tickâ€borne viral zoonosis with a caseâ€fatality rate ranging from 9% to 50% in humans. Although a licensed vaccine to prevent infection by the CCHF virus (CCHFV) exists, its ability to induce neutralizing antibodies is limited and its efficacy against CCHFV remains undetermined. In addition, controlling CCHF infections by eradication of the tick reservoir has been ineffective, both economically and logistically, and the treatment optio
Document: Crimean–Congo haemorrhagic fever (CCHF) is a widespread tickâ€borne viral zoonosis with a caseâ€fatality rate ranging from 9% to 50% in humans. Although a licensed vaccine to prevent infection by the CCHF virus (CCHFV) exists, its ability to induce neutralizing antibodies is limited and its efficacy against CCHFV remains undetermined. In addition, controlling CCHF infections by eradication of the tick reservoir has been ineffective, both economically and logistically, and the treatment options for CCHF remain limited. In this review, we first critically discuss the existing animal models to evaluate therapeutics for CCHF. We then review the therapeutic options for CCHF that have been investigated in human cases, followed by investigational drugs that have been evaluated in preâ€clinical studies. We highlight the importance of understanding human prognostic factors in developing an animal model for CCHF that recapitulates hallmarks of human disease and its implication for selecting therapeutic candidates.
Search related documents:
Co phrase search for related documents- activator signal transducer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute disease and adenovirus infection: 1, 2, 3, 4, 5
- acute disease and adequate training: 1, 2
- acute disease and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8
- acute disease and local hospital: 1, 2, 3
- acute disease and long hospitalization time: 1
- acute disease and long term sequelae: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute disease and loss fever: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute respiratory syndrome and additional marker: 1, 2
- acute respiratory syndrome and adenovirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and adequate antibody response: 1, 2, 3, 4
- acute respiratory syndrome and adequate training: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and local hospital: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and logistically economically: 1
- acute respiratory syndrome and long term sequelae: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adenovirus infection and local hospital: 1
- adequate training and local hospital: 1
Co phrase search for related documents, hyperlinks ordered by date